-
公开(公告)号:PL195273B1
公开(公告)日:2007-08-31
申请号:PL33879198
申请日:1998-08-27
Applicant: VERTEX PHARMA
Inventor: MCCAFFREY PATRICIA , NOVAK PERRY M , MULLICAN MICHAEL
IPC: C07D401/12 , A61K31/44 , A61K31/4406 , A61K31/4427 , A61K31/4458 , A61K31/4545 , A61P25/04 , A61P25/16 , A61P25/28 , C07D211/60 , C07D213/40 , C07D401/14
-
公开(公告)号:ID23675A
公开(公告)日:2000-05-11
申请号:ID20000402
申请日:1998-08-27
Applicant: VERTEX PHARMA
Inventor: PATRICIA MCCAFEREY , NOVAK PERRY M , MICHAEL MULLICAN
IPC: A61K31/4406 , A61K31/4427 , A61K31/4458 , A61K31/4545 , A61P25/04 , A61P25/16 , A61P25/28 , C07D211/60 , C07D213/40 , C07D401/12 , C07D401/14 , A61K31/44 , A61K31/445
-
公开(公告)号:NO20000953A
公开(公告)日:2000-05-02
申请号:NO20000953
申请日:2000-02-25
Applicant: VERTEX PHARMA
Inventor: MCCAFFREY PATRICIA , NOVAK PERRY M , MULLICAN MICHAEL D
IPC: A61K31/4406 , A61K31/4427 , A61K31/4458 , A61K31/4545 , A61P25/04 , A61P25/16 , A61P25/28 , C07D211/60 , C07D213/40 , C07D401/12 , C07D401/14 , A61K31/44 , A61P25/00 , C07D413/40
CPC classification number: C07D213/40 , C07D211/60 , C07D401/12 , C07D401/14
-
公开(公告)号:BG102945A
公开(公告)日:1999-08-31
申请号:BG10294598
申请日:1998-11-23
Applicant: VERTEX PHARMA
Inventor: ARMISTEAD DAVID M , BADIA MICHAEL C , BEMIS GUY W , BETHIEL RANDY S , FRANK CATHARINE A , NOVAK PERRY M , RONKIN STEVEN M , SAUNDERS JEFFREY O
IPC: A61K31/17 , A61K31/18 , A61K31/404 , A61K31/42 , A61K31/421 , A61K31/422 , A61P9/14 , A61P29/00 , A61P31/12 , A61P35/00 , A61P37/06 , A61P43/00 , C07C275/42 , C07D263/18 , C07D263/32 , C07D277/18 , C07D413/12 , C07C275/28 , C07C275/34
Abstract: The invention relates to a new class of compounds which areinhibitors of IMPDH enzyme activity. They have the formulawhere A, D and B have the meanings listed in the description. Theinvention also relates to pharmaceutical compositions containingthese compounds and to methods for IMPDH activity inhibition byusing them.53 claims
-
公开(公告)号:CZ9803380A3
公开(公告)日:1999-02-17
申请号:CZ338098
申请日:1997-04-21
Applicant: VERTEX PHARMA
Inventor: ARMISTEAD DAVID M , BADIA MICHAEL C , BEMIS GUY W , BETHIEL RANDY S , FRANK CATHARINE A , NOVAK PERRY M , RONKIN STEVEN M , SAUNDERS JEFFREY O
IPC: A61K31/17 , A61K31/18 , A61K31/404 , A61K31/42 , A61K31/421 , A61K31/422 , A61P9/14 , A61P29/00 , A61P31/12 , A61P35/00 , A61P37/06 , A61P43/00 , C07C275/42 , C07D263/18 , C07D263/32 , C07D277/18 , C07D413/12 , C07C275/28 , C07C275/34
CPC classification number: C07D413/12 , A61K31/404 , A61K31/42 , A61K31/422 , C07C275/42 , C07D263/32 , Y02P20/55
-
公开(公告)号:NO984917L
公开(公告)日:1998-12-23
申请号:NO984917
申请日:1998-10-22
Applicant: VERTEX PHARMA
Inventor: ARMISTEAD DAVID M , BADIA MICHAEL C , BEMIS GUY W , BETHIEL RADNY S , FRANK CATHARINE A , NOVAK PERRY M , RONKIN STEVEN M , SAUNDERS JEFFREY O
IPC: A61K31/17 , A61K31/18 , A61K31/404 , A61K31/42 , A61K31/421 , A61K31/422 , A61P9/14 , A61P29/00 , A61P31/12 , A61P35/00 , A61P37/06 , A61P43/00 , C07C275/42 , C07D263/18 , C07D263/32 , C07D277/18 , C07D413/12
Abstract: The present invention relates to a novel class of compounds which are IMPDH inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting IMPDH enzyme activity and consequently, may be advantageously used as therapeutic agents for IMPDH mediated processes. This invention also relates to methods for inhibiting the activity of IMPDH using the compounds of this invention and related compounds.
-
公开(公告)号:NO984917A
公开(公告)日:1998-12-23
申请号:NO984917
申请日:1998-10-22
Applicant: VERTEX PHARMA
Inventor: ARMISTEAD DAVID M , BADIA MICHAEL C , BEMIS GUY W , BETHIEL RADNY S , FRANK CATHARINE A , NOVAK PERRY M , RONKIN STEVEN M , SAUNDERS JEFFREY O
IPC: A61K31/17 , A61K31/18 , A61K31/404 , A61K31/42 , A61K31/421 , A61K31/422 , A61P9/14 , A61P29/00 , A61P31/12 , A61P35/00 , A61P37/06 , A61P43/00 , C07C275/42 , C07D263/18 , C07D263/32 , C07D277/18 , C07D413/12
CPC classification number: C07D413/12 , A61K31/404 , A61K31/42 , A61K31/422 , C07C275/42 , C07D263/32 , Y02P20/55
-
公开(公告)号:ZA9703397B
公开(公告)日:1997-11-14
申请号:ZA9703397
申请日:1997-04-21
Applicant: VERTEX PHARMA
Inventor: ARMISTEAD DAVID M , BADIA MICHAEL C , BEMIS GUY W , BETHIEL RANDY S , FRANK CATHARINE A , NOVAK PERRY M , RONKIN STEVEN M , SAUNDERS JEFFREY O
IPC: A61K31/17 , A61K31/18 , A61K31/404 , A61K31/42 , A61K31/421 , A61K31/422 , A61P9/14 , A61P29/00 , A61P31/12 , A61P35/00 , A61P37/06 , A61P43/00 , C07C275/42 , C07D263/18 , C07D263/32 , C07D277/18 , C07D413/12 , C07C , A61K , C07D
CPC classification number: C07D413/12 , A61K31/404 , A61K31/42 , A61K31/422 , C07C275/42 , C07D263/32
-
公开(公告)号:CZ298463B6
公开(公告)日:2007-10-10
申请号:CZ338098
申请日:1997-04-21
Applicant: VERTEX PHARMA
Inventor: ARMISTEAD DAVID M , BADIA MICHAEL C , BEMIS GUY W , BETHIEL RANDY S , FRANK CATHARINE A , NOVAK PERRY M , RONKIN STEVEN M , SAUNDERS JEFFREY O
IPC: C07D413/12 , A61K31/17 , A61K31/18 , A61K31/404 , A61K31/42 , A61K31/421 , A61K31/422 , A61P9/14 , A61P29/00 , A61P31/12 , A61P35/00 , A61P37/06 , A61P43/00 , C07C275/28 , C07C275/34 , C07C275/42 , C07D263/18 , C07D263/32 , C07D277/18
Abstract: Použití derivátu mocoviny obecného vzorce I, k príprave léciva inhibujícího aktivitu IMPDH u savce,a nekteré takové deriváty mocoviny. Farmaceuticképrostredky obsahující tyto deriváty mocoviny jsouurceny pro lécení nebo prevenci onemocnení zprostredkovaného IMPDH u savce.
-
公开(公告)号:NZ502820A
公开(公告)日:2002-10-25
申请号:NZ50282098
申请日:1998-08-27
Applicant: VERTEX PHARMA
Inventor: MCCAFFREY PATRICIA , NOVAK PERRY M , MULLICAN MICHAEL
IPC: A61K31/4406 , A61K31/4427 , A61K31/4458 , A61K31/4545 , A61P25/04 , A61P25/16 , A61P25/28 , C07D211/60 , C07D213/40 , C07D401/12 , C07D401/14 , A61K31/44 , A61K31/445
Abstract: A compound of the formula (I) and its derivatives can be used, either alone or in conjunction with a neurotrophic factor, such as nerve growth factor, to promote repair of neuronal damage caused by disease or physical trauma, where: A and B are H, Ar, or optionally substituted alkyl, alkenyl or alkynyl, where any one of the CH2 groups of alkyl, alkenyl or alkynyl chains in A or B is optionally replaced by O, S, S(O), S(O)2 OR N(R); Ar is defined in the specification; n is 0 - 2; X is N, O or C(R), when X is N or C(R), Y is H, Ar, or optionally substituted alkyl, alkenyl or alkynyl and when X is O, Y is a lone pair of electrons; R is H, alkyl, alkenyl or alkynyl; K is optionally substituted alkyl, alkenyl or alkynyl, or cyclohexylmethyl, where any one of the CH2 groups of alkyl, alkenyl or alkynyl chains in K is optionally replaced by O, S, S(O), S(O)2 OR N(R); J is H, optionally substituted alkyl, alkenyl or alkynyl, or cyclohexylmethyl D is Ar, or optionally substituted alkyl, alkenyl or alkynyl, or cyclohexylmethyl, where any one of the CH2 groups of alkyl chains in D other than the one that is directly bound to the S(O)2 is optionally replaced by O, S, S(O), S(O)2 OR N(R); and that the compound of formula (I) is not (S)-(2-(5-(dimethylamino)-1-naphthalenesulfanilamido)-3-phenyl)carboxylic acid, 1-(pyridin-4-yl) propyl ester or (S)-(p-toluenesulfanilamido)-3-phenyl-N-(2-pyridin-2-yl)methyl)propionamide; and provided that (i) when X is N, n is 0 and Y is H or alkyl; or (ii) when X is O n is 0; or (iii) when X is C-H, n is 0 and Y is H; then D is Ar, or optionally substituted alkyl, alkenyl or alkynyl, or cyclohexylmethyl, where any one of the CH2 groups of alkyl chains in D other than the one that is directly bound to the S(O)2 is optionally replaced by O, S, S(O), S(O)2 OR N(R).
-
-
-
-
-
-
-
-
-